… summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small …
… of ALK inhibitors has included more patients with BrM from the outset, our literature review
… The development programs for second-generation drugs alectinib, ceritinib, and brigatinib …
… The development programs for second-generation drugs alectinib, ceritinib, and brigatinib …
Development of novel therapeutic strategies in relapsed advanced/metastatic non-small cell lung cancer
N Tokaca - 2022 - repository.icr.ac.uk
Recent advances in the treatment of advanced NSCLC include introduction of targeted
therapies and immune-checkpoint inhibitors, leading to improvements in survival outcomes. …
therapies and immune-checkpoint inhibitors, leading to improvements in survival outcomes. …